| Primary |
| Non-small Cell Lung Cancer |
21.9% |
| Gastric Cancer |
14.6% |
| Prophylaxis |
8.0% |
| Pain |
4.6% |
| Hypertension |
4.6% |
| Gastrooesophageal Cancer |
4.4% |
| Nausea |
4.1% |
| Testis Cancer |
4.0% |
| Oesophageal Carcinoma |
3.7% |
| Head And Neck Cancer |
3.6% |
| Squamous Cell Carcinoma |
3.5% |
| Small Cell Lung Cancer Stage Unspecified |
3.3% |
| Germ Cell Cancer |
3.0% |
| Metastatic Gastric Cancer |
2.9% |
| Lung Neoplasm Malignant |
2.6% |
| Constipation |
2.4% |
| Neoplasm Malignant |
2.3% |
| Non-small Cell Lung Cancer Stage Iii |
2.3% |
| Prophylaxis Of Nausea And Vomiting |
2.1% |
| Premedication |
2.0% |
|
| Vomiting |
21.0% |
| White Blood Cell Count Decreased |
7.6% |
| Thrombocytopenia |
6.7% |
| Pulmonary Embolism |
6.6% |
| Renal Failure Acute |
6.2% |
| Neutropenia |
5.5% |
| Pyrexia |
5.3% |
| Weight Decreased |
4.9% |
| Sepsis |
4.2% |
| Stomatitis |
3.6% |
| Febrile Neutropenia |
3.5% |
| Nausea |
3.5% |
| Renal Failure |
3.5% |
| Dehydration |
3.3% |
| Mucosal Inflammation |
2.8% |
| Pneumonia |
2.7% |
| Syncope |
2.5% |
| Urinary Tract Infection |
2.4% |
| Neutrophil Count Decreased |
2.3% |
| Deep Vein Thrombosis |
2.0% |
|
| Secondary |
| Non-small Cell Lung Cancer |
19.9% |
| Prophylaxis |
11.9% |
| Gastric Cancer |
9.7% |
| Head And Neck Cancer |
9.5% |
| Multiple Myeloma |
6.5% |
| Drug Use For Unknown Indication |
6.1% |
| Product Used For Unknown Indication |
3.5% |
| Oesophageal Carcinoma |
3.4% |
| Gastrooesophageal Cancer |
3.3% |
| Squamous Cell Carcinoma |
3.3% |
| Hypertension |
3.2% |
| Pain |
3.2% |
| Nausea |
2.8% |
| Bone Sarcoma |
2.7% |
| Non-hodgkin's Lymphoma |
1.9% |
| Lung Neoplasm Malignant |
1.9% |
| Metastatic Gastric Cancer |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.8% |
| Premedication |
1.8% |
| Mantle Cell Lymphoma |
1.7% |
|
| Vomiting |
14.7% |
| Thrombocytopenia |
8.9% |
| Pulmonary Embolism |
7.6% |
| Neutropenia |
6.8% |
| White Blood Cell Count Decreased |
6.0% |
| Sepsis |
5.2% |
| Death |
4.9% |
| Pneumonia |
4.8% |
| Febrile Neutropenia |
4.8% |
| Pyrexia |
4.6% |
| Weight Decreased |
4.0% |
| Renal Failure |
3.9% |
| Renal Failure Acute |
3.9% |
| Off Label Use |
3.8% |
| Stomatitis |
3.0% |
| Mucosal Inflammation |
3.0% |
| Septic Shock |
2.6% |
| General Physical Health Deterioration |
2.6% |
| Nausea |
2.5% |
| Dyspnoea |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.9% |
| Product Used For Unknown Indication |
12.4% |
| Non-small Cell Lung Cancer |
11.6% |
| Chemotherapy |
6.8% |
| Prophylaxis |
6.5% |
| Prophylaxis Of Nausea And Vomiting |
5.6% |
| Lung Adenocarcinoma |
5.3% |
| Premedication |
3.9% |
| Lung Neoplasm Malignant |
3.9% |
| Gastric Cancer |
3.8% |
| Diffuse Large B-cell Lymphoma |
3.2% |
| Squamous Cell Carcinoma |
2.7% |
| Multiple Myeloma |
2.7% |
| Lung Adenocarcinoma Stage Iv |
2.7% |
| Hypertension |
2.5% |
| Pain |
2.3% |
| Transitional Cell Carcinoma |
2.2% |
| Head And Neck Cancer |
2.1% |
| Metastases To Bone |
2.0% |
| Metastatic Gastric Cancer |
2.0% |
|
| Vomiting |
15.2% |
| Thrombocytopenia |
10.7% |
| White Blood Cell Count Decreased |
8.5% |
| Death |
7.5% |
| Pyrexia |
6.1% |
| Pulmonary Embolism |
5.5% |
| Neutropenia |
4.9% |
| Sepsis |
4.8% |
| Weight Decreased |
3.9% |
| Febrile Neutropenia |
3.6% |
| Nausea |
3.6% |
| Renal Failure Acute |
3.6% |
| Renal Failure |
3.4% |
| Pneumonia |
3.1% |
| Interstitial Lung Disease |
2.8% |
| Diarrhoea |
2.6% |
| Pancytopenia |
2.6% |
| Platelet Count Decreased |
2.6% |
| Respiratory Failure |
2.6% |
| Myocardial Infarction |
2.5% |
|
| Interacting |
| Chemotherapy |
12.9% |
| Bile Duct Cancer |
11.0% |
| Glioblastoma Multiforme |
11.0% |
| Product Used For Unknown Indication |
9.2% |
| Malignant Hydatidiform Mole |
6.1% |
| Gastric Cancer |
5.5% |
| General Anaesthesia |
5.5% |
| Bone Sarcoma |
3.7% |
| Essential Thrombocythaemia |
3.7% |
| Hiv Infection |
3.7% |
| Lung Carcinoma Cell Type Unspecified Stage Iv |
3.7% |
| Lung Neoplasm Malignant |
3.7% |
| Mantle Cell Lymphoma |
3.7% |
| Gestational Trophoblastic Tumour |
3.1% |
| Urethral Cancer |
3.1% |
| Status Epilepticus |
2.5% |
| Urinary Tract Infection |
2.5% |
| Mental Disorder |
1.8% |
| Pain |
1.8% |
| Squamous Cell Carcinoma |
1.8% |
|
| Pyrexia |
15.8% |
| Pancytopenia |
10.5% |
| Drug Interaction |
7.9% |
| Diarrhoea |
5.3% |
| Hallucination, Visual |
5.3% |
| Muscle Haemorrhage |
5.3% |
| Ophthalmoplegia |
5.3% |
| Paralysis |
5.3% |
| Renal Impairment |
5.3% |
| Reversible Posterior Leukoencephalopathy Syndrome |
5.3% |
| Vomiting |
5.3% |
| Cholangitis Sclerosing |
2.6% |
| Haematotoxicity |
2.6% |
| International Normalised Ratio Increased |
2.6% |
| Malnutrition |
2.6% |
| Mucosal Inflammation |
2.6% |
| Off Label Use |
2.6% |
| Platelet Count Decreased |
2.6% |
| Pneumatosis Intestinalis |
2.6% |
| Renal Failure Acute |
2.6% |
|
